Abstract
This randomized study evaluated the efficacy and tolerability of continued treatment with protease inhibitor plus nucleoside-analogue combination regimens (n = 79) or a change to the simplified regimen of abacavir-lamivudine-zidovudine (n = 84) in patients with suppressed human immunodeficiency virus type 1 (HIV-1) RNA for ≥ 6 months who did not have the reverse transcriptase 215 mutation. After a median follow-up of 84 weeks, virologic failure was 6% in the continuation and 15% in the simplified group (P = .081). Previous zidovudine monotherapy or dual therapy and archived reverse transcriptase resistance mutations in HIV-1 DNA at baseline were significant predictors of failure. Study treatment was discontinued because of adverse events in 20% of the continuation and 7% of the simplified group (P = .021). Simplification to abacavir-lamivudine-zidovudine significantly decreased nonfasting cholesterol and triglyceride levels; however, this switch strategy carries a risk of virologic failure when treatment history or resistance testing suggest the presence of archived resistance mutations to the simplified regimen.
| Original language | English |
|---|---|
| Pages (from-to) | 1251-1260 |
| Number of pages | 10 |
| Journal | Journal of Infectious Diseases |
| Volume | 185 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - May 1 2002 |
Fingerprint
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Immunology
Cite this
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. / Opravil, Milos; Hirschel, Bernard; Lazzarin, Adriano; Furrer, Hansjakob; Chave, Jean Philippe; Yerly, Sabine; Bisset, Leslie R.; Fischer, Marek; Vernazza, Pietro; Bernasconi, Enos; Battegay, Manuel; Ledergerber, Bruno; Günthard, Huldrych; Howe, Colin; Weber, Rainer; Perrin, Luc.
In: Journal of Infectious Diseases, Vol. 185, No. 9, 01.05.2002, p. 1251-1260.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection
AU - Opravil, Milos
AU - Hirschel, Bernard
AU - Lazzarin, Adriano
AU - Furrer, Hansjakob
AU - Chave, Jean Philippe
AU - Yerly, Sabine
AU - Bisset, Leslie R.
AU - Fischer, Marek
AU - Vernazza, Pietro
AU - Bernasconi, Enos
AU - Battegay, Manuel
AU - Ledergerber, Bruno
AU - Günthard, Huldrych
AU - Howe, Colin
AU - Weber, Rainer
AU - Perrin, Luc
PY - 2002/5/1
Y1 - 2002/5/1
N2 - This randomized study evaluated the efficacy and tolerability of continued treatment with protease inhibitor plus nucleoside-analogue combination regimens (n = 79) or a change to the simplified regimen of abacavir-lamivudine-zidovudine (n = 84) in patients with suppressed human immunodeficiency virus type 1 (HIV-1) RNA for ≥ 6 months who did not have the reverse transcriptase 215 mutation. After a median follow-up of 84 weeks, virologic failure was 6% in the continuation and 15% in the simplified group (P = .081). Previous zidovudine monotherapy or dual therapy and archived reverse transcriptase resistance mutations in HIV-1 DNA at baseline were significant predictors of failure. Study treatment was discontinued because of adverse events in 20% of the continuation and 7% of the simplified group (P = .021). Simplification to abacavir-lamivudine-zidovudine significantly decreased nonfasting cholesterol and triglyceride levels; however, this switch strategy carries a risk of virologic failure when treatment history or resistance testing suggest the presence of archived resistance mutations to the simplified regimen.
AB - This randomized study evaluated the efficacy and tolerability of continued treatment with protease inhibitor plus nucleoside-analogue combination regimens (n = 79) or a change to the simplified regimen of abacavir-lamivudine-zidovudine (n = 84) in patients with suppressed human immunodeficiency virus type 1 (HIV-1) RNA for ≥ 6 months who did not have the reverse transcriptase 215 mutation. After a median follow-up of 84 weeks, virologic failure was 6% in the continuation and 15% in the simplified group (P = .081). Previous zidovudine monotherapy or dual therapy and archived reverse transcriptase resistance mutations in HIV-1 DNA at baseline were significant predictors of failure. Study treatment was discontinued because of adverse events in 20% of the continuation and 7% of the simplified group (P = .021). Simplification to abacavir-lamivudine-zidovudine significantly decreased nonfasting cholesterol and triglyceride levels; however, this switch strategy carries a risk of virologic failure when treatment history or resistance testing suggest the presence of archived resistance mutations to the simplified regimen.
UR - http://www.scopus.com/inward/record.url?scp=0036569234&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036569234&partnerID=8YFLogxK
U2 - 10.1086/340312
DO - 10.1086/340312
M3 - Article
C2 - 12001042
AN - SCOPUS:0036569234
VL - 185
SP - 1251
EP - 1260
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 9
ER -